Biotech Specialty Pharma

Embera NeuroTherapeutics

29 Babe Ruth Drive
Sudbury, MA 01776 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Novel treatments for smoking cessation and cocaine dependence

Management Robert B. Linke, President and Chief Executive Officer; Carol Gloff, Ph.D., Vice President, Pre-Clinical Development and Regulatory Affairs; Michael Detke, M.D., PhD, Chief Medical Officer; Gary Connor, RN, Director of Clinical Operations

Click here for Financial Data
Keywords: alcohol, cocaine addiction, nicotine, smoking cessation, obesity, mental health


Updated: Oct. 23, 2015


Embera NeuroTherapeutics, Inc. (Embera) is a clinical stage pharma company based in Boston, MA focused on smoking cessation, cocaine dependence and other addictions, diseases with a very limited range......view more

Products / Services

EMB-001 is a patented combination drug product comprising two FDA-approved medications. EMB-001 acts by mechanisms distinct from those of existing drug dependence treatments. The innovation is based o......view more

Technology / Differentiation

EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on new insights ...view more

Market / Customers

Smoking cessation is a $1.9B WW market ($1.0B in the US). Of the 43M US smokers, 23M try to quit each year. A new, effective therapy would have a significant market impact. Pfizers smoking cessation ......view more

Competitors / Substitutes / Alternatives

Big pharma with significant revenues in the smoking cessation market include Pfizer, GSK, Novartis & J&J. Worldwide revenue of the leading products include: Chantix - $650M and Nicotine Replacement Th...view more

Revenue / Funding

Funding to Date: $6.2M in investor capital and $4M in non-dilutive grant funding. Financing Sought: $2M to fund phase 1 safety and pharmacokinetic study in otherwise healthy smokers and fund comp...view more


The FDA has completed it review of the EMB-001 IND allowing our Phase 1 study in smokers to proceed pending completion of our current financing. In addition, a significant NIH grant to fund the EMB-00...view more


Companys Law Firm Corporate Counsel: Gunderson Dettmer,Stough, Villeneuve, Franklin & Hachigan, LLP Patent Counsel: Duane Morris, LLP Companys Banker Johnston Blakely Companys Accounting F...view more